BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

979 related articles for article (PubMed ID: 23846820)

  • 1. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
    Ganie MA; Khurana ML; Eunice M; Gupta N; Gulati M; Dwivedi SN; Ammini AC
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2756-62. PubMed ID: 15181054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome.
    Iwata MC; Porquere L; Sorpreso IC; Baracat EC; Soares Júnior JM
    Rev Assoc Med Bras (1992); 2015; 61(3):215-9. PubMed ID: 26248242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin therapy in women with polycystic ovary syndrome.
    Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
    Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
    Zheng YH; Wang XH; Lai MH; Yao H; Liu H; Ma HX
    J Altern Complement Med; 2013 Sep; 19(9):740-5. PubMed ID: 23676106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A; Agarwal N
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.